H Thomas Temple1. 1. Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. htemple@med.miami.edu
Abstract
PURPOSE OF REVIEW: Giant cell tumor of tendon sheath and pigmented villonodular synovitis are synovial-based diseases that are generally treated by surgery. For aggressive and recurrent tumors, treatment alternatives are needed. This review explores a targeted therapeutic strategy. RECENT FINDINGS: Imatinib, a tyrosine kinase inhibitor, blocks expression of colony stimulating factor 1 (CSF1) by a small subpopulation of tumor cells that recruit CSF1-bearing nonneoplastic cells. Limited clinical data support the efficacy and side effect profile of imatinib in stabilizing disease in most patients. SUMMARY: Imatinib along with other such inhibitors and monoclonal antibodies to CSF1R are putative drugs that may play an important role in the treatment of these tumors.
PURPOSE OF REVIEW: Giant cell tumor of tendon sheath and pigmented villonodular synovitis are synovial-based diseases that are generally treated by surgery. For aggressive and recurrent tumors, treatment alternatives are needed. This review explores a targeted therapeutic strategy. RECENT FINDINGS:Imatinib, a tyrosine kinase inhibitor, blocks expression of colony stimulating factor 1 (CSF1) by a small subpopulation of tumor cells that recruit CSF1-bearing nonneoplastic cells. Limited clinical data support the efficacy and side effect profile of imatinib in stabilizing disease in most patients. SUMMARY:Imatinib along with other such inhibitors and monoclonal antibodies to CSF1R are putative drugs that may play an important role in the treatment of these tumors.
Authors: James H Lewis; Hans Gelderblom; Michiel van de Sande; Silvia Stacchiotti; John H Healey; William D Tap; Andrew J Wagner; Antonio Lopez Pousa; Mihaela Druta; Chia-Chi Lin; Hideo A Baba; Youngsook Choi; Qiang Wang; Dale E Shuster; Sebastian Bauer Journal: Oncologist Date: 2020-12-24
Authors: Vaishali Malik; Hayat Anu Ranjani; Anujan Ramesh; Harriet Smith; Ashish A Kulkarni Journal: Drug Deliv Transl Res Date: 2021-08-07 Impact factor: 4.617